Albertson T E, Walby W F
Neuropharmacology. 1987 Feb-Mar;26(2-3):261-4. doi: 10.1016/0028-3908(87)90217-6.
The effects of 12 daily doses of 30 mg/kg GM1 ganglioside i.p. on the acquisition of kindled-amygdaloid seizures in the rat was studied. No modification in the rate of kindling or the expression of the elicited seizures was noted during the acquisition phase. Further studies with additional fully amygdaloid kindled rats failed to show significant modification of suprathreshold or threshold elicited seizures after single 30-60 mg/kg i.p. doses of GM1 ganglioside. Despite previous studies which have shown antibodies to GM1 ganglioside to be convulsive, no anticonvulsant activity was demonstrated in this study with exogenous GM1 ganglioside using a battery of kindled-amygdaloid seizure tests in the rat.
研究了腹腔注射12天、每天剂量为30mg/kg的GM1神经节苷脂对大鼠杏仁核点燃性癫痫发作获得的影响。在发作获得阶段,未观察到点燃率或诱发癫痫发作的表现有改变。对另外一些完全杏仁核点燃的大鼠进一步研究发现,腹腔注射30 - 60mg/kg剂量的GM1神经节苷脂后,阈上或阈下诱发的癫痫发作无显著改变。尽管先前的研究表明GM1神经节苷脂抗体具有惊厥作用,但在本研究中,采用一系列大鼠杏仁核点燃性癫痫发作试验,未证明外源性GM1神经节苷脂具有抗惊厥活性。